Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2019-10-01 Regulatory Filings
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document text is very short (1498 characters) and contains an 'RNS Number' and explicitly mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a direct, non-standard regulatory announcement distributed via the RNS system, and it doesn't fit the specific definitions for AGM-R, DVA, DIRS, etc., the most appropriate classification is the general regulatory announcement fallback category, RNS.
2019-10-01 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1481 characters) and contains the header 'RNS Number : 4068O'. It announces a 'Price Monitoring Extension' related to trading activity on the London Stock Exchange. This type of brief, operational announcement, especially one explicitly referencing RNS (the news service of the London Stock Exchange) and its role as a Primary Information Provider, fits best under the general regulatory announcement category, as it does not correspond to a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS, CAP). Therefore, the fallback category 'Regulatory Filings' (RNS) is the most appropriate classification.
2019-10-01 English
Interim Results Announcement
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for ImmuPharma PLC for the six months ended 30 June 2019. It contains detailed financial highlights, a Chairman's statement, a financial review, and operational updates. Since it provides substantive financial data and analysis for a period shorter than a full fiscal year, it qualifies as an Interim/Quarterly Report (IR). H1 2019
2019-09-30 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1483 characters) and contains the header 'RNS Number : 8615M'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. This type of brief, operational announcement, especially one explicitly referencing RNS (the news service of the London Stock Exchange) and its role as a Primary Information Provider, fits best under the general regulatory announcement category, as it does not correspond to a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS, MANG). Therefore, the fallback category 'Regulatory Filings' (RNS) is the most appropriate classification.
2019-09-18 English
TR-1: notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is explicitly identified by the header 'RNS Number : 4235E' and contains the standard format 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds). This directly corresponds to the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2019-07-04 English
TR-1: notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 2541E' and the concluding statement mentioning 'RNS, the news service of the London Stock Exchange.' The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership thresholds (crossing from 18.17% to 15.14% for Dr Robert Zimmer). This type of mandatory disclosure regarding significant changes in shareholding is a specific regulatory filing. While it is a regulatory filing, the specific nature points directly to 'Major Shareholding Notification' (MRQ). However, since TR-1 forms are often categorized broadly under regulatory announcements, and given the options, MRQ is the most precise fit for a major holding notification. If MRQ were not available, RNS would be the fallback. Since MRQ is available and perfectly describes the content (notification of major holdings), I select MRQ.
2019-07-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.